Paper40144486
Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies.
Tharwat M and 2 others. World J Clin Cases, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies. Papers, record 40144486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40144486
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31262915 | Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer. | Anticancer Res | 2019 | https://conductscience.org/library/papers/31262915 | PubMed |
| 2 | 38798717 | Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events. | JHEP Rep | 2024 | https://conductscience.org/library/papers/38798717 | PubMed |
| 3 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 4 | 33032274 | Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas. | Oncology | 2021 | https://conductscience.org/library/papers/33032274 | PubMed |
| 5 | 32402160 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32402160 | PubMed |
| 6 | 38398229 | Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38398229 | PubMed |
| 7 | 22776219 | Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report. | J Med Case Rep | 2012 | https://conductscience.org/library/papers/22776219 | PubMed |
| 8 | 36883351 | Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort. | Aliment Pharmacol Ther | 2023 | https://conductscience.org/library/papers/36883351 | PubMed |
| 9 | 36426410 | Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. | Cancer | 2023 | https://conductscience.org/library/papers/36426410 | PubMed |
| 10 | 34377156 | Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. | Ther Adv Med Oncol | 2021 | https://conductscience.org/library/papers/34377156 | PubMed |
| 11 | 34902530 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. | J Hepatol | 2022 | https://conductscience.org/library/papers/34902530 | PubMed |
| 12 | 38201624 | Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38201624 | PubMed |
| 13 | 24124381 | Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. | Onco Targets Ther | 2013 | https://conductscience.org/library/papers/24124381 | PubMed |
| 14 | 39109046 | Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report. | World J Clin Cases | 2024 | https://conductscience.org/library/papers/39109046 | PubMed |
| 15 | 33982923 | Lenvatinib-Induced Tumor-Related Hemorrhage in Patients With Unresectable Hepatocellular Carcinoma. | Am J Gastroenterol | 2021 | https://conductscience.org/library/papers/33982923 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40144486
GET https://conductscience.org/api/papers/v1/40144486/authors